ArticleClinical and experimental immunology2017
Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4
Article in Clinical and experimental immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 60 citations in OpenAlex.
- Topical framework nucleic acid transdermal delivery system for reprogramming cutaneous dendritic cells to maintain graft immune homeostasis.Bioactive materials · 2026Article
- Advanced Immunomodulation in Rheumatoid Arthritis: Immune Checkpoints, microRNAs, and Cell-Based Therapies.Biomedicines · 2025Review
- Article
- Leveraging current insights on IL-10-producing dendritic cells for developing effective immunotherapeutic approaches.FEBS letters · 2025Review
- Cell-Based Therapeutic Strategies for Autoimmune Diseases.ImmunoTargets and therapy · 2025Review
- Arginine vasopressin (AVP) treatment increases the expression of inhibitory immune checkpoint molecules in monocyte-derived dendritic cells.Immunologic research · 2024Article
- Myelin Oligodendrocyte Glycoprotein (MOG)35-55 Mannan Conjugate Induces Human T-Cell Tolerance and Can Be Used as a Personalized Therapy for Multiple Sclerosis.International journal of molecular sciences · 2024Article
- Cell and biomaterial delivery strategies to induce immune tolerance.Advanced drug delivery reviews · 2023Review
- The mechanism of dendritic cell-T cell crosstalk in rheumatoid arthritis.Arthritis research & therapy · 2023Review
- Effect of DMARDs on the immunogenicity of vaccines.Nature reviews. Rheumatology · 2023Review
- Tolerogenic dendritic cells generatedFrontiers in immunology · 2023Article
- Tolerogenic dendritic cells in radiation-induced lung injury.Frontiers in immunology · 2023Review
- Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration.Immunotherapy advances · 2023Review
- Liposomes loaded with vitamin D3 induce regulatory circuits in human dendritic cells.Frontiers in immunology · 2023Article
- Tolerogenic dendritic cell reporting: Has a minimum information model made a difference?PeerJ · 2023Article
- The role of dendritic cells and their immunometabolism in rheumatoid arthritis.Frontiers in immunology · 2023Review
- In Vitro Generation of Human Tolerogenic Monocyte-Derived Dendritic Cells.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Regulation of Myeloid Dendritic Cells by Synthetic and Natural Compounds for the Treatment of Rheumatoid Arthritis.International journal of molecular sciences · 2022Review
- MicroRNA-10b promotes arthritis development by disrupting CD4Molecular therapy. Nucleic acids · 2022Article
- Fluorine labelling of therapeutic human tolerogenic dendritic cells forFrontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
Abstract
Tolerogenic dendritic cells (tolDC) are a new immunotherapeutic tool for the treatment of rheumatoid arthritis (RA) and other autoimmune disorders. We have established a method to generate stable tolDC by pharmacological modulation of human monocyte-derived DC. These tolDC exert potent pro-tolerogenic actions on CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.